Skip to main content

Table 4 Prevalence of cervical and oral HPV infection according to the HIV-related parameters

From: Cervical and oral human papillomavirus infection in women living with human immunodeficiency virus (HIV) and matched HIV-negative controls in Brazil

VariablesHPV+ (N = 56)OR (CI)PCervical HPV+ (N = 51)OR (CI)POral HPV+ (N = 11)OR (CI)P
N (%)N (%)N (%)
Documented HIV infection (years)
  < 539/73 (53.4)1.68 (0.79–3.60)0.2436/73 (49.3)1.75 (0.81–3.71)0.187/73 (9.6)1.00 (0.28–3.23)> 0.99
 5–1017/42 (40.5)115/42 (35.7)1 4/42 (9.5)1 
  > 100/0 (0) 
Compliance to HAART
 Yes42/93 (45.2)0.46 (0.18–1.17)0.1539/93 (41.9)0.60 (0.22–1.50)0.349/93 (9.7)1.07 (0.23–5.25)> 0.99
 No14/22 (66.6)112/22 (54.5)1 2/22 (9.1)1 
Most recent CD4 (cells/mm3)
  < 2003/3 (100)3/3 (100)0/3 (0)
 200–3509/17 (52.9)1.30 (0.47–3.78)0.798/17 (47.1)1.22 (0.41–3.34)0.792/17 (11.8)1.27 (0.25–6.01)0.67
  > 35044/95 (46.3)140/95 (42.1)1 9/95 (9.5)1 
Most recent viral load
 Undetectable44/99 (44.4)139/99 (39.4)1 11/99 (11.1)1
 Detectable12/16 (75.0)3.75 (1.22–11.10)0.0312/16 (75.0)4.61 (1.50–13.66)0.010/16 (0) 
  1. HPV = human papillomavirus, HIV = human immunodeficiency virus, HAART, highly active antiretroviral therapy; OR = Odds ratio; CI = confidence interval